Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

137 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Pharmacology of imatinib (STI571).
Buchdunger E, O'Reilly T, Wood J. Buchdunger E, et al. Eur J Cancer. 2002 Sep;38 Suppl 5:S28-36. doi: 10.1016/s0959-8049(02)80600-1. Eur J Cancer. 2002. PMID: 12528770 Review.
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.
Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger E, Black PM, Stiles CD. Kilic T, et al. Cancer Res. 2000 Sep 15;60(18):5143-50. Cancer Res. 2000. PMID: 11016641
Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.
Soni R, O'Reilly T, Furet P, Muller L, Stephan C, Zumstein-Mecker S, Fretz H, Fabbro D, Chaudhuri B. Soni R, et al. J Natl Cancer Inst. 2001 Mar 21;93(6):436-46. doi: 10.1093/jnci/93.6.436. J Natl Cancer Inst. 2001. PMID: 11259469
Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
O'Reilly T, Wartmann M, Maira SM, Hattenberger M, Vaxelaire J, Muller M, Ferretti S, Buchdunger E, Altmann KH, McSheehy PMJ. O'Reilly T, et al. Cancer Chemother Pharmacol. 2005 Apr;55(4):307-317. doi: 10.1007/s00280-004-0913-z. Epub 2004 Oct 26. Cancer Chemother Pharmacol. 2005. PMID: 15723258
Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O'Reilly T, Lane H, Susa M. Kneissel M, et al. Bone. 2004 Nov;35(5):1144-56. doi: 10.1016/j.bone.2004.07.013. Bone. 2004. PMID: 15542040
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
O'Reilly T, McSheehy PM, Wartmann M, Lassota P, Brandt R, Lane HA. O'Reilly T, et al. Anticancer Drugs. 2011 Jan;22(1):58-78. doi: 10.1097/CAD.0b013e3283400a20. Anticancer Drugs. 2011. PMID: 20890178
Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM. O'Reilly T, et al. Cancer Chemother Pharmacol. 2008 Nov;62(6):1045-54. doi: 10.1007/s00280-008-0695-9. Epub 2008 Feb 27. Cancer Chemother Pharmacol. 2008. PMID: 18301895
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T, Wood J. LaMontagne K, et al. Cancer Res. 2006 Jan 1;66(1):221-31. doi: 10.1158/0008-5472.CAN-05-2001. Cancer Res. 2006. PMID: 16397235
Combined treatment strategies for microtubule stabilizing agent-resistant tumors.
Broggini-Tenzer A, Sharma A, Nytko KJ, Bender S, Vuong V, Orlowski K, Hug D, O'Reilly T, Pruschy M. Broggini-Tenzer A, et al. J Natl Cancer Inst. 2015 Feb 17;107(4):dju504. doi: 10.1093/jnci/dju504. Print 2015 Apr. J Natl Cancer Inst. 2015. PMID: 25694444
Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
O'Reilly T, Lane HA, Wood JM, Schnell C, Littlewood-Evans A, Brueggen J, McSheehy PM. O'Reilly T, et al. Cancer Chemother Pharmacol. 2011 Jan;67(1):193-200. doi: 10.1007/s00280-010-1307-z. Epub 2010 May 30. Cancer Chemother Pharmacol. 2011. PMID: 20512579
137 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback